These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 30951862)

  • 1. PDE10A mutations help to unwrap the neurobiology of hyperkinetic disorders.
    Whiteley EL; Tejeda GS; Baillie GS; Brandon NJ
    Cell Signal; 2019 Aug; 60():31-38. PubMed ID: 30951862
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of the striatal specific phosphodiesterase PDE10A ameliorates striatal and cortical pathology in R6/2 mouse model of Huntington's disease.
    Giampà C; Laurenti D; Anzilotti S; Bernardi G; Menniti FS; Fusco FR
    PLoS One; 2010 Oct; 5(10):e13417. PubMed ID: 20976216
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biallelic Mutations in PDE10A Lead to Loss of Striatal PDE10A and a Hyperkinetic Movement Disorder with Onset in Infancy.
    Diggle CP; Sukoff Rizzo SJ; Popiolek M; Hinttala R; Schülke JP; Kurian MA; Carr IM; Markham AF; Bonthron DT; Watson C; Sharif SM; Reinhart V; James LC; Vanase-Frawley MA; Charych E; Allen M; Harms J; Schmidt CJ; Ng J; Pysden K; Strick C; Vieira P; Mankinen K; Kokkonen H; Kallioinen M; Sormunen R; Rinne JO; Johansson J; Alakurtti K; Huilaja L; Hurskainen T; Tasanen K; Anttila E; Marques TR; Howes O; Politis M; Fahiminiya S; Nguyen KQ; Majewski J; Uusimaa J; Sheridan E; Brandon NJ
    Am J Hum Genet; 2016 Apr; 98(4):735-43. PubMed ID: 27058446
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Striatal phosphodiesterase mRNA and protein levels are reduced in Huntington's disease transgenic mice prior to the onset of motor symptoms.
    Hebb AL; Robertson HA; Denovan-Wright EM
    Neuroscience; 2004; 123(4):967-81. PubMed ID: 14751289
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chorea-related mutations in PDE10A result in aberrant compartmentalization and functionality of the enzyme.
    Tejeda GS; Whiteley EL; Deeb TZ; Bürli RW; Moss SJ; Sheridan E; Brandon NJ; Baillie GS
    Proc Natl Acad Sci U S A; 2020 Jan; 117(1):677-688. PubMed ID: 31871190
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of phosphodiesterase 10A, dopamine receptors D1 and D2 and dopamine transporter ligand binding in the striatum of the R6/2 and BACHD mouse models of Huntington's disease.
    Miller S; Hill Della Puppa G; Reidling J; Marcora E; Thompson LM; Treanor J
    J Huntingtons Dis; 2014; 3(4):333-41. PubMed ID: 25575954
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phosphodiesterase-10A Inverse Changes in Striatopallidal and Striatoentopeduncular Pathways of a Transgenic Mouse Model of
    D'Angelo V; Castelli V; Giorgi M; Cardarelli S; Saverioni I; Palumbo F; Bonsi P; Pisani A; Giampà C; Sorge R; Biagioni S; Fusco FR; Sancesario G
    J Neurosci; 2017 Feb; 37(8):2112-2124. PubMed ID: 28115486
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phosphodiesterase 10A (PDE10A) localization in the R6/2 mouse model of Huntington's disease.
    Leuti A; Laurenti D; Giampà C; Montagna E; Dato C; Anzilotti S; Melone MA; Bernardi G; Fusco FR
    Neurobiol Dis; 2013 Apr; 52():104-16. PubMed ID: 23220622
    [TBL] [Abstract][Full Text] [Related]  

  • 9. De Novo Mutations in PDE10A Cause Childhood-Onset Chorea with Bilateral Striatal Lesions.
    Mencacci NE; Kamsteeg EJ; Nakashima K; R'Bibo L; Lynch DS; Balint B; Willemsen MA; Adams ME; Wiethoff S; Suzuki K; Davies CH; Ng J; Meyer E; Veneziano L; Giunti P; Hughes D; Raymond FL; Carecchio M; Zorzi G; Nardocci N; Barzaghi C; Garavaglia B; Salpietro V; Hardy J; Pittman AM; Houlden H; Kurian MA; Kimura H; Vissers LE; Wood NW; Bhatia KP
    Am J Hum Genet; 2016 Apr; 98(4):763-71. PubMed ID: 27058447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of the striatum-enriched phosphodiesterase PDE10A: a novel approach to the treatment of psychosis.
    Siuciak JA; Chapin DS; Harms JF; Lebel LA; McCarthy SA; Chambers L; Shrikhande A; Wong S; Menniti FS; Schmidt CJ
    Neuropharmacology; 2006 Aug; 51(2):386-96. PubMed ID: 16780899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PET imaging shows loss of striatal PDE10A in patients with Huntington disease.
    Ahmad R; Bourgeois S; Postnov A; Schmidt ME; Bormans G; Van Laere K; Vandenberghe W
    Neurology; 2014 Jan; 82(3):279-81. PubMed ID: 24353339
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronic suppression of phosphodiesterase 10A alters striatal expression of genes responsible for neurotransmitter synthesis, neurotransmission, and signaling pathways implicated in Huntington's disease.
    Kleiman RJ; Kimmel LH; Bove SE; Lanz TA; Harms JF; Romegialli A; Miller KS; Willis A; des Etages S; Kuhn M; Schmidt CJ
    J Pharmacol Exp Ther; 2011 Jan; 336(1):64-76. PubMed ID: 20923867
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Altered PDE10A expression detectable early before symptomatic onset in Huntington's disease.
    Niccolini F; Haider S; Reis Marques T; Muhlert N; Tziortzi AC; Searle GE; Natesan S; Piccini P; Kapur S; Rabiner EA; Gunn RN; Tabrizi SJ; Politis M
    Brain; 2015 Oct; 138(Pt 10):3016-29. PubMed ID: 26198591
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PDE10A and PDE10A-dependent cAMP catabolism are dysregulated oppositely in striatum and nucleus accumbens after lesion of midbrain dopamine neurons in rat: a key step in parkinsonism physiopathology.
    Giorgi M; Melchiorri G; Nuccetelli V; D'Angelo V; Martorana A; Sorge R; Castelli V; Bernardi G; Sancesario G
    Neurobiol Dis; 2011 Jul; 43(1):293-303. PubMed ID: 21515371
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of Exogenous NUB1 Expression in the Striatum of HDQ175/Q7 Mice.
    Vodicka P; Chase K; Iuliano M; Valentine DT; Sapp E; Lu B; Kegel-Gleason KB; Sena-Esteves M; Aronin N; DiFiglia M
    J Huntingtons Dis; 2016 Jun; 5(2):163-74. PubMed ID: 27314618
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alterations in gene regulation following inhibition of the striatum-enriched phosphodiesterase, PDE10A.
    Strick CA; James LC; Fox CB; Seeger TF; Menniti FS; Schmidt CJ
    Neuropharmacology; 2010 Feb; 58(2):444-51. PubMed ID: 19765598
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current Understanding of PDE10A in the Modulation of Basal Ganglia Circuitry.
    Schülke JP; Brandon NJ
    Adv Neurobiol; 2017; 17():15-43. PubMed ID: 28956328
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PDE10A and ADCY5 mutations linked to molecular and microstructural basal ganglia pathology.
    Niccolini F; Mencacci NE; Yousaf T; Rabiner EA; Salpietro V; Pagano G; Balint B; Efthymiou S; Houlden H; Gunn RN; Wood N; Bhatia KP; Politis M
    Mov Disord; 2018 Dec; 33(12):1961-1965. PubMed ID: 30345538
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic deletion of the striatum-enriched phosphodiesterase PDE10A: evidence for altered striatal function.
    Siuciak JA; McCarthy SA; Chapin DS; Fujiwara RA; James LC; Williams RD; Stock JL; McNeish JD; Strick CA; Menniti FS; Schmidt CJ
    Neuropharmacology; 2006 Aug; 51(2):374-85. PubMed ID: 16769090
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TAK-063, a Novel Phosphodiesterase 10A Inhibitor, Protects from Striatal Neurodegeneration and Ameliorates Behavioral Deficits in the R6/2 Mouse Model of Huntington's Disease.
    Harada A; Suzuki K; Kimura H
    J Pharmacol Exp Ther; 2017 Jan; 360(1):75-83. PubMed ID: 27811172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.